Annual EBITDA:
-$85.38M-$15.37M(-21.96%)Summary
- As of today, TSHA annual EBITDA is -$85.38 million, with the most recent change of -$15.37 million (-21.96%) on December 31, 2024.
- During the last 3 years, TSHA annual EBITDA has risen by +$87.40 million (+50.59%).
- TSHA annual EBITDA is now -7557.04% below its all-time high of -$1.11 million, reached on December 31, 2019.
Performance
TSHA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$26.48M-$5.34M(-25.25%)Summary
- As of today, TSHA quarterly EBITDA is -$26.48 million, with the most recent change of -$5.34 million (-25.25%) on June 30, 2025.
- Over the past year, TSHA quarterly EBITDA has dropped by -$5.48 million (-26.08%).
- TSHA quarterly EBITDA is now -2274.53% below its all-time high of -$1.11 million, reached on December 1, 2019.
Performance
TSHA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$88.00M-$5.48M(-6.64%)Summary
- As of today, TSHA TTM EBITDA is -$88.00 million, with the most recent change of -$5.48 million (-6.64%) on June 30, 2025.
- Over the past year, TSHA TTM EBITDA has dropped by -$12.26 million (-16.19%).
- TSHA TTM EBITDA is now -7792.56% below its all-time high of -$1.11 million, reached on December 1, 2019.
Performance
TSHA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TSHA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -22.0% | -26.1% | -16.2% |
| 3Y3 Years | +50.6% | +19.1% | +50.9% |
| 5Y5 Years | -7557.0% | - | -304.8% |
TSHA EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -22.0% | +50.6% | -73.0% | at low | -26.9% | +42.8% |
| 5Y | 5-Year | -7557.0% | +50.6% | -76.0% | +47.6% | -304.8% | +53.0% |
| All-Time | All-Time | -7557.0% | +50.6% | -2274.5% | +47.6% | -7792.6% | +53.0% |
TSHA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$26.48M(-25.3%) | -$88.00M(-6.6%) |
| Mar 2025 | - | -$21.14M(-7.7%) | -$82.53M(+3.4%) |
| Dec 2024 | -$85.38M(-22.0%) | -$19.63M(+5.5%) | -$85.39M(-5.2%) |
| Sep 2024 | - | -$20.76M(+1.1%) | -$81.19M(-7.2%) |
| Jun 2024 | - | -$21.00M(+12.5%) | -$75.74M(+2.2%) |
| Mar 2024 | - | -$24.00M(-55.6%) | -$77.42M(-11.6%) |
| Dec 2023 | -$70.00M(+43.3%) | -$15.43M(-0.8%) | -$69.34M(+2.2%) |
| Sep 2023 | - | -$15.30M(+32.5%) | -$70.93M(+12.2%) |
| Jun 2023 | - | -$22.68M(-42.4%) | -$80.81M(+11.1%) |
| Mar 2023 | - | -$15.93M(+6.4%) | -$90.86M(+25.2%) |
| Dec 2022 | -$123.54M | -$17.02M(+32.4%) | -$121.42M(+21.1%) |
| Sep 2022 | - | -$25.18M(+23.1%) | -$153.91M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$32.74M(+29.6%) | -$179.25M(+4.2%) |
| Mar 2022 | - | -$46.48M(+6.1%) | -$187.20M(-8.3%) |
| Dec 2021 | -$172.78M(-301.9%) | -$49.52M(+2.0%) | -$172.78M(-22.0%) |
| Sep 2021 | - | -$50.52M(-24.2%) | -$141.62M(-33.4%) |
| Jun 2021 | - | -$40.69M(-26.9%) | -$106.15M(-62.2%) |
| Mar 2021 | - | -$32.06M(-74.6%) | -$65.46M(-67.9%) |
| Dec 2020 | -$42.99M(-3755.9%) | - | - |
| Dec 2020 | - | -$18.36M(-22.1%) | -$38.99M(-79.3%) |
| Sep 2020 | - | -$15.04M(-169.4%) | -$21.74M(-224.5%) |
| Mar 2020 | - | -$5.58M(-400.8%) | -$6.70M(-500.8%) |
| Dec 2019 | -$1.11M | - | - |
| Dec 2019 | - | -$1.11M | -$1.11M |
FAQ
- What is Taysha Gene Therapies, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Taysha Gene Therapies, Inc.?
- What is Taysha Gene Therapies, Inc. annual EBITDA year-on-year change?
- What is Taysha Gene Therapies, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Taysha Gene Therapies, Inc.?
- What is Taysha Gene Therapies, Inc. quarterly EBITDA year-on-year change?
- What is Taysha Gene Therapies, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Taysha Gene Therapies, Inc.?
- What is Taysha Gene Therapies, Inc. TTM EBITDA year-on-year change?
What is Taysha Gene Therapies, Inc. annual EBITDA?
The current annual EBITDA of TSHA is -$85.38M
What is the all-time high annual EBITDA for Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. all-time high annual EBITDA is -$1.11M
What is Taysha Gene Therapies, Inc. annual EBITDA year-on-year change?
Over the past year, TSHA annual EBITDA has changed by -$15.37M (-21.96%)
What is Taysha Gene Therapies, Inc. quarterly EBITDA?
The current quarterly EBITDA of TSHA is -$26.48M
What is the all-time high quarterly EBITDA for Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. all-time high quarterly EBITDA is -$1.11M
What is Taysha Gene Therapies, Inc. quarterly EBITDA year-on-year change?
Over the past year, TSHA quarterly EBITDA has changed by -$5.48M (-26.08%)
What is Taysha Gene Therapies, Inc. TTM EBITDA?
The current TTM EBITDA of TSHA is -$88.00M
What is the all-time high TTM EBITDA for Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. all-time high TTM EBITDA is -$1.11M
What is Taysha Gene Therapies, Inc. TTM EBITDA year-on-year change?
Over the past year, TSHA TTM EBITDA has changed by -$12.26M (-16.19%)